Dr. John Mendlein, the CEO of Adnexus Therapeutics Inc., (Adnexus), a privately held biotechnology company, must resolve whether to pursue acquisition talks with Bristol-Myers Squibb (BMS) after a successful six month cooperation or continue with Adnexus' planned IPO.
PUBLICATION DATE: November 11, 2008 PRODUCT #: 609015-PDF-ENG
This is just an excerpt. This case is about LEADERSHIP & MANAGING PEOPLE
Related Case Solutions & Analyses:
The Saffola Journey
Human Resources, Social Media Policies and the Law in Canada
Contesting the Value of “Creating Shared Value”
Managing Value in Supply Chains: Case Studies on the Sourcing Hub Concept
Implementation of a Hybrid Operating Room for Cardiac Surgery at the Sainte-Justine University Hospital: Collaboration and Change Management Challenges
Pulmocit (B): Negotiating Pharmaceutical Products with the Government
A Sought-After Visa For Entering China’s Electronic Payment Market and Strategies Beyond
INDUSTRIAL AND COMMERCIAL BANK OF CHINA: GOVERNANCE LESSONS FROM EAST TO WEST
Leading Across Cultures at Michelin (C)
Blair Howard: Developing an Exceptional Presentation (A)
